Kera Capital Partners Inc. Has $1.25 Million Position in Kyverna Therapeutics, Inc. $KYTX

Kera Capital Partners Inc. reduced its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 68.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 132,603 shares of the company’s stock after selling 289,321 shares during the period. Kera Capital Partners Inc.’s holdings in Kyverna Therapeutics were worth $1,246,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. AIGH Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics during the fourth quarter worth $14,100,000. RFG Advisory LLC acquired a new stake in Kyverna Therapeutics during the fourth quarter valued at $4,185,000. Simplify Asset Management Inc. purchased a new position in Kyverna Therapeutics in the fourth quarter valued at about $1,808,000. Maven Securities LTD purchased a new position in Kyverna Therapeutics in the fourth quarter valued at about $1,376,000. Finally, Monashee Investment Management LLC purchased a new position in Kyverna Therapeutics in the fourth quarter valued at about $1,833,000. 18.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. reduced their price target on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.00.

Kyverna Therapeutics Stock Up 0.4%

KYTX stock opened at $8.07 on Friday. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13. Kyverna Therapeutics, Inc. has a 1 year low of $2.52 and a 1 year high of $13.67. The company has a fifty day simple moving average of $8.91 and a 200 day simple moving average of $8.56. The firm has a market cap of $490.58 million, a PE ratio of -2.46 and a beta of 1.95.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. Sell-side analysts anticipate that Kyverna Therapeutics, Inc. will post -2.78 EPS for the current fiscal year.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.